Wang, Xiaojia
Zhejiang Cancer Hospital
2 papers on CoChatORCID 0000-0001-5043-2459
Most cited papers
- Verified
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 270
- Verified
Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.
Lu, S., Zhang, Q., Meng, X., Sun, Y., Xiong, H. H., Lv, D., Wang, X., Wu, L., Dong, X., Ji, Y., et al. (2024) · Journal of Clinical Oncology
Cancer therapeutics and mechanismsMonoclonal and Polyclonal Antibodies Research
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free